John M.H. Gregg, CLP

About

Start-up and pharmaceutical industry veteran, John M.H. Gregg, has extensive experience in forming and successfully exiting infectious disease companies. His expertise is in worldwide clinical development and commercialization of microbiological products, new anti-infectives, and oncology drugs, most recently with an FDA approval in September 2017 of Solosec (secnidazole). He has spent much of his career directing the commercialization efforts for a large number of antibiotic, anti-protozoal, anti-fungal and anti-viral drugs as well as therapeutics in multiple other therapeutic areas, including immunology, oncology, and neuroscience. He is an industry leader in biotech company development, serving as CEO of specialty infectious disease start-ups like his current company, BalinBac, now focused on developing direct antivirals for COVID-19.

Source (opens in a new tab)